Skip to main content

Table 1 Baseline Characteristics According to TyG index level

From: Association between triglyceride glucose index and worsening heart failure in significant secondary mitral regurgitation following percutaneous coronary intervention

Characteristic

TyG index level

P-value

Overall

T1 (≤ 8.51)

T2 (> 8.51, ≤ 8.98)

T3 (> 8.98)

N = 922

N = 307

N = 306

N = 309

Demographic characteristics

 Male

734 (79.6)

261 (84.5)

240 (78.4)

233 (75.9)

0.025

 Age, years

64.1 (11.0)

64.3 (11.4)

65.4 (11.0)

62.6 (10.5)

0.006

 BMI, kg/m2

23.8 (3.4)

23.5 (3.4)

23.5 (3.3)

24.2 (3.6)

0.021

 Heart rate, bmp

82.1 (17.4)

81.0 (16.6)

81.3 (18.6)

84.0 (16.7)

0.059

 SBP, mmHg

128.1 (22.8)

126.9 (22.6)

128.7 (22.1)

128.6 (23.7)

0.566

 DBP, mmHg

75.6 (12.9)

75.5 (13.4)

75.5 (12.2)

75.7 (13.2)

0.96

 History of smoke

0.025

  Never

567 (61.5)

185 (59.9)

180 (58.8)

202 (65.8)

 

  Cessation

139 (15.1)

59 (19.1)

49 (16.0)

31 (10.1)

 

  Current

216 (23.4)

65 (21.0)

77 (25.2)

74 (24.1)

 

Medical history

 Anemia

404 (43.8)

145 (46.9)

134 (43.8)

125 (40.7)

0.299

 CHF

416 (45.1)

131 (42.4)

139 (45.4)

146 (47.6)

0.433

 DM

404 (43.8)

145 (46.9)

134 (43.8)

125 (40.7)

 < 0.001

 CKD

341 (37.0)

100 (32.4)

112 (36.6)

129 (42.0)

0.045

 Hypertension

552 (59.9)

183 (59.2)

183 (59.8)

186 (60.6)

0.942

 Hyperlipidemia

690 (74.8)

226 (73.1)

233 (76.1)

231 (75.2)

0.678

 AF

105 (11.4)

52 (16.8)

26 (8.5)

27 (8.8)

0.001

 COPD

29 (3.1)

10 (3.2)

11 (3.6)

8 (2.6)

0.777

 Stroke

39 (4.2)

15 (4.9)

12 (3.9)

12 (3.9)

0.8

 History of PCI

119 (12.9)

40 (12.9)

38 (12.4)

41 (13.4)

0.942

 History of AMI

99 (10.7)

29 (9.4)

31 (10.1)

39 (12.7)

0.378

 Clinical presentation

  AMI

343 (37.2)

101 (32.7)

116 (37.9)

126 (41.0)

0.095

  STEMI

227 (24.6)

72 (23.3)

75 (24.5)

80 (26.1)

0.728

  NSTEMI

116 (12.6)

29 (9.4)

41 (13.4)

46 (15.0)

0.097

Laboratory test

 LDL-C, mmol/L

2.88 (1.10)

2.77 (1.05)

2.95 (1.19)

2.91 (1.06)

0.117

 HDL-C, mmol/L

0.97 (0.27)

0.98 (0.28)

0.97 (0.27)

0.96 (0.28)

0.75

 eGFR, mL/min/1.73m2

69.6 (26.0)

73.5 (27.4)

68.6 (23.9)

66.8 (26.1)

0.004

 ALB, g/L

35.0 (4.6)

34.5 (4.1)

35.3 (5.1)

35.1 (4.5)

0.088

 NT-proBNP, ng/L

2092 [903, 4826]

2414 [1169, 5311]

1864 [860, 4606]

1739 [749, 4816]

0.04

 hs-cTnT, ng/L

0.71 [0.22, 7.33]

0.64 [0.22, 4.20]

0.62 [0.22, 6.33]

1.13 [0.23, 9.89]

0.169

 LVEF, %

43.8 (13.7)

42.8 (13.6)

45.5 (13.9)

43.2 (13.4)

0.029

 LVEDD, mm

43.3 (10.7)

44.1 (10.8)

42.5 (10.6)

43.3 (10.5)

0.165

 LVESD, mm

56.6 (8.5)

57.3 (8.7)

56.1 (8.5)

56.5 (8.4)

0.22

 Left atrial, mm

41.2 (6.3)

41.7 (6.3)

41.0 (6.7)

41.1 (6.0)

0.309

Procedural characteristics

 Radial artery access

754 (81.8)

256 (82.8)

247 (80.7)

251 (81.8)

0.791

 Multivessel disease

789 (85.6)

263 (85.1)

261 (85.3)

265 (86.3)

0.9

 Culprit vessel in STEMIs

0.945

  Left main coronary artery

7 (2.8)

1 (1.4)

3 (3.6)

3 (3.4)

 

  LAD

115 (46.6)

37 (50.0)

39 (46.4)

39 (43.8)

 

  LCX

41 (16.6)

11 (14.9)

13 (15.5)

17 (19.1)

 

  RCA

84 (34.0)

25 (33.8)

29 (34.5)

30 (33.7)

 

 Number of vessels treated

1.45 (0.68)

1.41 (0.67)

1.49 (0.68)

1.44 (0.69)

0.346

 Number of lesions treated

1.67 (0.89)

1.63 (0.89)

1.70 (0.86)

1.68 (0.94)

0.62

 Number of stents

1.91 (1.18)

1.92 (1.16)

1.92 (1.24)

1.90 (1.15)

0.96

 Minimum stent diameter, mm

2.69 (0.75)

2.70 (0.77)

2.64 (0.80)

2.72 (0.69)

0.413

 Lesion length, mm

52.3 (36.3)

52.5 (36.0)

52.5 (38.4)

52.0 (34.7)

0.977

Discharge prescription

 RAAS inhibitor

618 (67.0)

220 (71.2)

191 (62.4)

207 (67.4)

0.067

 Beta-blockers

781 (84.7)

265 (85.8)

254 (83.0)

262 (85.3)

0.594

 CCB

144 (15.6)

40 (12.9)

47 (15.4)

57 (18.6)

0.156

 Statin

856 (92.8)

287 (92.9)

286 (93.5)

283 (92.2)

0.827

 Aspirin

870 (94.4)

293 (94.8)

285 (93.1)

292 (95.1)

0.519

 Clopidogrel

807 (87.5)

276 (89.3)

267 (87.3)

264 (86.0)

0.451

 Loop diuretic

461 (50.0)

154 (49.8)

149 (48.7)

158 (51.5)

0.788

 MRA

467 (50.7)

160 (51.8)

149 (48.7)

158 (51.5)

0.702

 Hypoglycemic drugs

199 (21.9)

40 (13.0)

67 (22.3)

92 (30.7)

 < 0.001

 Insulin

40 (4.3)

10 (3.2)

10 (3.3)

20 (6.5)

0.072

  1. Median (interquartile range). Lesion morphology assessed by operators
  2. AF atrial fibrillation, AMI acute myocardial infarction, ALB albumin, CHF congestive heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CCB calcium channel blockers, DBP diastolic blood pressure, DM diabetes mellitus, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, hs-cTnT Hypersensitive troponin T, LDL-C low-density lipoprotein cholesterol, LAD left anterior descending coronary artery, LCX left circumflex coronary artery, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, MRA mineralcorticoid recept antagonist, NSTEMI non-ST-segment elevation myocardial infarction, NT-proBNP N-terminal pro brain natriuretic peptide, TyG index Triglyceride–glucose index, PCI percutaneous coronary intervention, RAAS inhibitor renin–angiotensin–aldosterone system inhibitor, RCA right coronary artery, SBP systolic blood pressure, STEMI ST-segment elevation myocardial infarction